Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women. Lubiprostone is generally well tolerated, with nausea being the most common adverse event. AIMS: To characterize nausea with lubiprostone using pooled results from clinical studies in patients with CIC, OIC, or IBS-C. METHODS: Data from three 3- and 4-week placebo-controlled studies and three long-term open-label studies were pooled for the CIC analysis. The OIC and IBS-C analyses each used pooled data from three 12-week placebo-controlled studies and one 36-week open-label extension study. RESULTS: The populations included the following numbers of patients: CIC, 316 (placebo) and 1113 (lubiprostone 24 mcg twice daily [BID]); OIC, 652 (placebo) and 889 (lubiprostone 24 mcg BID); and IBS-C, 435 (placebo) and 1011 (lubiprostone 8 mcg BID). The incidence of nausea in lubiprostone-treated patients ranged from 11.4 to 31.1%, with the highest incidence in patients with CIC. Among patients with any nausea, most reported only mild or moderate severity (96.5-99.1% across indications) and only one event (83.6-88.7%); most events occurred within the first 5 days of treatment. CONCLUSIONS: Nausea was the most common adverse event following the treatment with lubiprostone. Event rates varied by indication and dose, and the majority of nausea adverse events were mild to moderate in severity. Nausea events predominantly occurred early in the treatment period in all of the pooled study populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of nausea is dose-dependent and seems to be lower when taken with food and water. 63”
From American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023) · cites this paper as [63]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pare, P., Ferrazzi, S., Thompson, W. G., Irvine, E. J., & Rance, L. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05259.x · Cited by 439
Severe chronic constipation of young women: 'idiopathic slow transit constipation'.
Preston, D. M., & Lennard-Jones, J. E. (1986) · Gut · doi:10.1136/gut.27.1.41 · Cited by 403
DROSSMAN, D. A., CHEY, W. D., JOHANSON, J. F., FASS, R., SCOTT, C., PANAS, R., & UENO, R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03881.x · Cited by 399 · cited 1×
“For IBS-C treatment, data were from three randomized, double-blind, 12-week, placebo-controlled studies (NCT00380250 and NCT00399542 [13], and a third study [14]) and one 36-week open-label extension study (continuation of NCT00380250 and NCT00399542) [15].”
MethodSelf-citationJohanson, J. F., Morton, D., Geenen, J., & Ueno, R. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01524.x · Cited by 331
Chronic Constipation in the Elderly
Gallegos-Orozco, J. F., Foxx-Orenstein, A. E., Sterler, S. M., & Stoa, J. M. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.349 · Cited by 297
Chronic Constipation in the Elderly
Bouras, E. P., & Tangalos, E. G. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.06.001 · Cited by 275
Camilleri, M., Bharucha, A. E., Ueno, R., Burton, D., Thomforde, G. M., Baxter, K., McKinzie, S., & Zinsmeister, A. R. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00264.2005 · Cited by 253
JOHANSON, J. F., & UENO, R. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03320.x · Cited by 230
Kepenekci, I., Keskinkilic, B., Akinsu, F., Cakir, P., Elhan, A. H., Erkek, A. B., & Kuzu, M. A. (2011) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181fd2356 · Cited by 208
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation
JOHANSON, J. F., DROSSMAN, D. A., PANAS, R., WAHLE, A., & UENO, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03629.x · Cited by 204
Self-citationAdverse Effects Associated with Non-opioid and Opioid Treatment in Patients with Chronic Pain
Labianca, R., Sarzi-Puttini, P., Zuccaro, S. M., Cherubino, P., Vellucci, R., & Fornasari, D. (2012) · Clinical Drug Investigation · doi:10.2165/11630080-000000000-00000 · Cited by 201
Cumulative incidence of chronic constipation: a population‐based study 1988–2003
CHOUNG, R. S., LOCKE III, G. R., SCHLECK, C. D., ZINSMEISTER, A. R., & TALLEY, N. J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03540.x · Cited by 194
Efficacy and safety of lubiprostone in patients with chronic constipation
Barish, C. F., Drossman, D., Johanson, J. F., & Ueno, R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1068-x · Cited by 192 · cited 1×
“Three of the CIC studies were randomized, double-blind, placebo-controlled trials lasting 3–4 weeks [5, 7, 8], and two were open-label 24- and 48-week extension studies [9, 10].”
BackgroundSelf-citationMcCrea, G. L., Miaskowski, C., Stotts, N. A., Macera, L., & Varma, M. G. (2009) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2008.04.016 · Cited by 167
Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia
Barbera, R., Feinle, C., & Read, N. W. (1995) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199511000-00007 · Cited by 129
Appendix: Jadad Scale for Reporting Randomized Controlled Trials
Halpern, S. H., & Douglas, M. J. (2005) · Wiley eBooks · doi:10.1002/9780470988343.app1 · Cited by 123
Chey, W. D., Drossman, D. A., Johanson, J. F., Scott, C., Panas, R. M., & Ueno, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04983.x · Cited by 121
Self-citationVoluntary suppression of defecation delays gastric emptying
Tjeerdsma, H. C., Smout, A. J. P. M., & Akkermans, L. M. A. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01295908 · Cited by 113
Fukudo, S., Hongo, M., Kaneko, H., Takano, M., & Ueno, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.026 · Cited by 110
Lembo, A. J., Johanson, J. F., Parkman, H. P., Rao, S. S., Miner, P. B., & Ueno, R. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1801-0 · Cited by 108
Jamal, M. M., Adams, A. B., Jansen, J.-P., & Webster, L. R. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.106 · Cited by 103
Self-citationCryer, B., Katz, S., Vallejo, R., Popescu, A., & Ueno, R. (2014) · Pain Medicine · doi:10.1111/pme.12437 · Cited by 99
Self-citationLubiprostone: A Chloride Channel Activator
Lacy, B. E., & Campbell Levy, L. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000225665.68920.df · Cited by 93
Chang, L., Chey, W. D., Drossman, D., Losch‐Beridon, T., Wang, M., Lichtlen, P., & Mareya, S. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13807 · Cited by 43
Self-citationManagement of chronic constipation in the elderly.
Kurniawan, I., & Simadibrata, M. (2011) · PubMed · Cited by 40
Hooks, S. B. S., Rutland, T. J., & Palma, J. A. D. (2009) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2009.04.045 · Cited by 39
Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome
Chamberlain, S., & Rao, S. S. C. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.708732 · Cited by 33
Song, J., Yin, J., Xu, X., & Chen, J. (2015) · PubMed Central · Cited by 8
Joswick, T. R., Spierings, E. L. H., Lindner, E., Woldegeorgis, F., & Rikitoshi, U. E. N. O. (2013) · Journal of Pain · doi:10.1016/j.jpain.2013.01.655 · Cited by 5
Ueno, R., Wahle, A., Panas, R. M., Joswick, T. R., & Rivera, E. (2006) · The American Journal of Gastroenterology · doi:10.14309/00000434-200609001-01269 · Cited by 5
Johanson, J. F., Gargano, M. A., Holland, P. C., Patchen, M. L., & Ueno, R. (2005) · The American Journal of Gastroenterology · doi:10.14309/00000434-200509001-00899 · Cited by 2
Chang, L., Chey, W. D., Drossman, D. A., Losch-Beridon, T. R., Wang, M., Lichtlen, P., & Mareya, S. M. (2015) · Gastroenterology · doi:10.1016/s0016-5085(15)32207-1 · Cited by 1
Self-citationMareya, S. M., Wang, M., Losch-Beridon, T. R., & Lichtlen, P. (2016) · Gastroenterology · doi:10.1016/s0016-5085(16)31839-x · Cited by 1
Self-citationLosch-Beridon, T. R., Mareya, S. M., Wang, M., & Lichtlen, P. (2016) · Gastroenterology · doi:10.1016/s0016-5085(16)31838-8 · Cited by 1
Self-citation
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Self-citationAmerican College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Self-citationBlack, C. J., & Ford, A. C. (2018) · Medical Journal of Australia · doi:10.5694/mja18.00241 · Cited by 228
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S., Greer, K. B., Hanson, B., Harris, L. A., Ko, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.214 · Cited by 185
Self-citationManagement Options for Irritable Bowel Syndrome
Camilleri, M. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.032 · Cited by 109
Metadata
- Authors
- Cryer, B., Drossman, D. A., Chey, W. D., Webster, L., Habibi, S., & Wang, M.
- Affiliations
- VA North Texas Health Care System (US)
- University of North Carolina at Chapel Hill (US)
- University of Michigan (US)
- PRA Health Sciences (US)
- Corresponding author
- Cryer, Byron
- Venue
- Digestive Diseases and Sciences
- Published
- 2017-08-28
- Volume
- 62
- Issue
- 12
- Pages
- 3568-3578
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- PMC
- PMC5694526
- OpenAlex
- W2748730319
- Cited by
- 43
- References
- 34
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 9 · 2019: 6 · 2018: 5 · 2017: 2
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Digestive Diseases and Sciences (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Sucampo Pharma Americas, LLC
- Takeda Pharmaceuticals International
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- lubiprostone, nausea, adverse events, chronic idiopathic constipation, opioid-induced constipation, irritable bowel syndrome with constipation, drug safety
- MeSH terms
- Lubiprostone, Constipation, Humans, Nausea, Chloride Channel Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.